Data Sheet 1_Humoral and cell mediated immune response to SARS-CoV-2 vaccination in patien

A prospective observational cohort study of 80 pediatric and adult patients with immune-mediated diseases and 12 healthy controls, conducted by Dorey A. Glenn between March 2021 and June 2022. It measures antibody neutralization and T-cell responses before and after initial and booster SARS-CoV-2 vaccination. The data was published on figshare in May 2026.

Use Cases

• Compare humoral immune response based on ACE2 neutralization percentages between patient cohorts.
• Assess the impact of anti-CD20 therapy on vaccine-induced antibody titers.
• Evaluate T-cell mediated immunity based on T-ELISpot counts in immunosuppressed individuals.
• Model the odds of achieving protective neutralization based on clinical factors like age, BMI, and comorbidities.

Strengths

• Includes longitudinal data with a median follow-up of 11.97 months.
• Provides specific quantitative results, such as a median neutralization of 46.9% for patients and 95.9% for controls.
• Explicitly analyzes the effect of anti-CD20 therapy, finding only 11.9% of exposed patients had protective titers.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single-center study, which may limit generalizability.

Provenance

Source

Dorey A. Glenn via figshare

Collection Method

Single-center, prospective observational cohort study.

Time Range

March 2021 to June 2022

Freshness

Last updated 2026-05-18 05:43:11; freshness should be verified.